Home / News / BioBlast™ Archive

BIOSIMILARS UPDATES

Our BioBlast™ Archive

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras aliquam neque id nisl suscipit elementum.

Pearce IP BioBlast™: w/e 26 February 2021

23 Feb 2021 | In its Q4 2020 investor presentation, Fresenius Kabi announced it will launch its biosimilar adalimumab in Australia in Q2 2021 and in Brazil in Q3 2021. Additionally, Fresenius Kabi announced it will launch its biosimilar...

Pearce IP BioBlast™: w/e 19 February 2021

13 Feb 2021 | Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution agreement with Korea's Prestige Biopharma for the commercialisation of Tuznue® (biosimilar trastuzumab). Under the agreement,...

Pearce IP BioBlast™: w/e 12 February 2021

04 Feb 2021 | Roche reported a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts and biosimilars. Roche reported the YoY CER growth of Avastin (bevacizumab) was -25%, with the hematology...

Pearce IP BioBlast™: w/e 05 February 2021

29 Jan 21 | EU | The CHMP recommended 13 medicines for approval. Among the recommendations were two bevacizumab biosimilars, Mabxience's Alymsys® and STADA's Oyavas®. 01 Feb 21 | CA | Celltrion announced it has received a notice of compliance...

Pearce IP BioBlast™: w/e 29 January 2021

25 Jan 21 | Samsung Bioepis announced the opening of its new headquarters in Incheon. The building was complete in December 2020, and will house approximately 1000 new employees, laboratory and office space. 27 Jan 21 | US | Health care...

Pearce IP BioBlast™: w/e 22 January 2021

18 Jan 21 | Prestige Biopharma announced it is set for an IPO in early February 2021. The IPO is expected to be worth US $348 million, with the majority of the funds to be reinvested in R&D. 18 Jan 21 | Innovent announced it has signed a...

Pearce IP BioBlast™: w/e 15 January 2021

07 Jan 21 | ADQ announced it will acquire Pharmax Pharmaceuticals, as well as investing in a minority stake in Biocon Biologics. 13 Jan 21 | Kamada announced it has entered into agreements with two undisclosed international pharmaceutical...

Pearce IP BioBlast™: w/e 08 January 2021

05 Jan 21 | EU | The Centre for Biosimilars reported a study presented at the 2020 San Antonio Breast Cancer Symposium found strong uptake of Amgen's Kanjinti (biosimilar trastuzumab) in Europe.     08 Jan 21 | A new study reviewed the use of...